Reviewing Embecta (NASDAQ:EMBC) and IceCure Medical (NASDAQ:ICCM)

IceCure Medical (NASDAQ:ICCM) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares IceCure Medical and Embecta”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38 million	0.88	-$15.06 million	($8.52)	-0.10
Embecta	$1.08 billion	0.33	$95.40 million	$1.48	4.22

Embecta has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IceCure Medical and Embecta’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
Embecta	8.59%	-19.25%	10.82%

Volatility and Risk

IceCure Medical has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Embecta has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for IceCure Medical and Embecta, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	1	1	2	0	2.25
Embecta	2	3	0	0	1.60

IceCure Medical presently has a consensus target price of $30.00, suggesting a potential upside of 3,347.88%. Embecta has a consensus target price of $11.00, suggesting a potential upside of 76.00%. Given IceCure Medical’s stronger consensus rating and higher probable upside, analysts plainly believe IceCure Medical is more favorable than Embecta.

Institutional & Insider Ownership

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by insiders. Comparatively, 1.3% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Embecta beats IceCure Medical on 9 of the 14 factors compared between the two stocks.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.